Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | GMNN | O75496 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4523555 | 1.00 | LMNA (0.54) | LMNASMN1; SMN2CYP1A2MAPTMAPK1 | |
| SCHEMBL27528807 | 0.84 | LMNA (0.56) | LMNASMN1; SMN2CYP1A2MAPTMAPK1 | |
| SCHEMBL28760186 | 0.84 | LMNA (0.56) | LMNASMN1; SMN2CYP1A2MAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL8896645 | 0.82 | LMNA (0.59) | LMNASMN1; SMN2CYP1A2MAPTMAPK1 | |
| SCHEMBL8975400 | 0.79 | MEN1 (0.38) | LMNASMN1; SMN2CYP1A2MAPTMEN1 | |
| SCHEMBL27987545 | 0.77 | LMNA (0.49) | LMNASMN1; SMN2CYP1A2MAPTMAPK1 | |
| SCHEMBL10080122 | 0.77 | LMNA (0.45) | LMNASMN1; SMN2CYP1A2MAPTMAPK1 | |
| SCHEMBL23148184 | 0.75 | LMNA (0.63) | LMNASMN1; SMN2CYP1A2MAPTMAPK1 | |
| SCHEMBL22057078 | 0.75 | LMNA (0.63) | LMNASMN1; SMN2CYP1A2MAPTMAPK1 | |
| SCHEMBL25099750 | 0.75 | LMNA (0.63) | LMNASMN1; SMN2CYP1A2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4125858-A1 | NUTRITIONAL COMPOSITION COMPRISING CARNITINE AND METHOD FOR TREATING OR PREVENTING AN INFECTION IN A MAMMAL | Lonza Consumer Health Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2021221741-A1 | NUTRITIONAL COMPOSITION COMPRISING CARNITINE AND METHOD FOR TREATING OR PREVENTING AN INFECTION IN A MAMMAL | LONZA CONSUMER HEALTH INC. (US) | 2021-11-04 | — | — | WO | claimed |
| EP-3164125-A2 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | Nan Global, LLC (US) | 2017-05-10 | — | — | EP | claimed |
| WO-2016004363-A2 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | NAN Global, LLC (US) | 2016-01-07 | — | — | WO | claimed |
| EP-1218001-A4 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA TAU HEALTHSCIENCE SPA (IT) | 2005-05-18 | — | — | EP | claimed |
| EP-1218001-A1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | Sigma-Tau Healthscience S.p.A. (IT) | 2002-07-03 | — | — | EP | claimed |
| WO-2001017525-A1 | ULTRAFINE L-CARNITINE, METHODS OF PREPARING THE SAME, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | SIGMA-TAU HEALTHSCUIENCE S.P.A (IT) | 2001-03-15 | — | — | WO | claimed |
| CN-114026427-A | Marker for diagnosing renal disease and diagnostic method | 深圳市中医院 | 2022-02-08 | — | — | CN | disclosed |
| CN-111803524-A | Oral pharmaceutical composition | 来必制药有限公司 | 2020-10-23 | — | — | CN | disclosed |
| US-7714166-B2 | Process for producing carnitinamide | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20090143616-A1 | Process for Producing Carnitinamide | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1930314-A1 | PROCESS FOR PRODUCING CARNITINAMIDE | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2008-06-11 | — | — | EP | disclosed |
| CN-1231460-C | Process for the preparation of (R)-or (S)-aminocarnitine inner salt, the salts and derivatives thereof | SIGMA TAU IND FARMACEUTI (IT) | 2005-12-14 | — | — | CN | disclosed |
| CN-1527811-A | Process for preparing -or (S) -aminocarnitine inner salt, and salts and derivatives thereof | ϣ��������ҩ��ҵ��˾ | 2004-09-08 | — | — | CN | disclosed |
| EP-1409448-A1 | PROCESS FOR THE PREPARATION OF (R)- OR (S)-AMINOCARNITINE INNER SALT, THE SALTS AND DERIVATIVES THEREOF | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003010129-A1 | PROCESS FOR THE PREPARATION OF (R)- OR (S)-AMINOCARNITINE INNER SALT, THE SALTS AND DERIVATIVES THEREOF | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143616-A1 | Process for Producing Carnitinamide | CRAT, NISCH, NAAA | LMNA 931/4885SMN1; SMN2 404/4885CYP1A2 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.